Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
Status:
Completed
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
This research is being done to determine if combining an investigational drug called
Everolimus with Rituximab can reduce the risk of your cancer from returning after high dose
chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins